Emotion Regulation Individual Therapy for Adolescents with Nonsuicidal Self-injury Disorder: a Feasibility Study
Overview
Authors
Affiliations
Background: Nonsuicidal self-injury (NSSI) is a serious health risk behavior that forms the basis of a tentative diagnosis in DSM-5, NSSI Disorder (NSSID). To date, established treatments specific to NSSI or NSSID are scarce. As a first step in evaluating the feasibility, acceptability, and utility of a novel treatment for adolescents with NSSID, we conducted an open trial of emotion regulation individual therapy for adolescents (ERITA): a 12-week, behavioral treatment aimed at directly targeting both NSSI and its proposed underlying mechanism of emotion regulation difficulties.
Methods: Seventeen girls (aged 13-17; mean = 15.31) with NSSID were enrolled in a study adopting an uncontrolled open trial design with self-report and clinician-rated assessments of NSSI and other self-destructive behaviors, emotion regulation difficulties, borderline personality features, and global functioning administered at pre-treatment, post-treatment, and 6-month follow-up. Measures of NSSI and emotion regulation difficulties were also administered weekly during treatment.
Results: Ratings of treatment credibility and expectancy and the treatment completion rate (88%) were satisfactory, and both therapeutic alliance and treatment attendance were strong. Intent-to-treat analyses revealed significant improvements associated with large effect sizes in past-month NSSI frequency, emotion regulation difficulties, self-destructive behaviors, and global functioning, as well as a medium effect size in past-month NSSI versatility, from pre- to post-treatment. Further, all of these improvements were either maintained or further improved upon at 6-month follow-up. Finally, change in emotion regulation difficulties mediated improvements in NSSI over the course of treatment.
Conclusions: Results suggest the acceptability, feasibility, and utility of this treatment for adolescents with NSSID.
Trial Registration: ClinicalTrials.gov (NCT02326012, December 22, 2014, retrospectively registered).
Larsson K, Zetterqvist M Front Psychiatry. 2025; 15:1448529.
PMID: 39822387 PMC: 11735939. DOI: 10.3389/fpsyt.2024.1448529.
Pan B, Gong Y, Guo M, Wang X, Lu H, Lin Z Neuropsychiatr Dis Treat. 2025; 21():1-13.
PMID: 39776896 PMC: 11701921. DOI: 10.2147/NDT.S498951.
Kruzan K, Biernesser C, Hoffmann J, Meyerhoff J Curr Treat Options Psychiatry. 2024; 11(2):76-89.
PMID: 39525358 PMC: 11548831. DOI: 10.1007/s40501-024-00318-9.
Ojala O, Hesser H, Gratz K, Tull M, Hedman-Lagerlof E, Sahlin H JCPP Adv. 2024; 4(3):e12243.
PMID: 39411472 PMC: 11472806. DOI: 10.1002/jcv2.12243.
Guerrero E, Andreasson K, Larsen L, Buus N, Skovgaard Larsen J, Krogh J Trials. 2024; 25(1):116.
PMID: 38341590 PMC: 10859016. DOI: 10.1186/s13063-024-07932-1.